DHEAS and cortisol/DHEAS-ratio in recurrent depression: State, or trait predicting 10-year recurrence?. (September 2015)

• Record Type: Journal Article
• Authors: Mocking, R.J.T.; Pellikaan, C.M.; Lok, A.; Assies, J.; Ruhé, H.G.; Koeter, M.W.; Visser, I.; Bockting, C.L.; Olff, M.; Schene, A.H.
• Is Part Of: Psychoneuroendocrinology. Volume 59(2015:Sep.)
• Page Start: 91
• Page End: 101
• Publication Date: 2015-09
• Subjects: Hypothalamic–pituitary–adrenal (HPA) axis -- Major depressive disorder (MDD) -- Dehydroepiandrosterone-sulphate (DHEAS) -- Cortisol -- Remission -- Recurrence; Psychoneuroendocrinology -- Periodicals; Endocrinology -- Periodicals; Neurology -- Periodicals; Psychiatry -- Periodicals; Neuropsychoendocrinologie -- Périodiques; 616.8
• DOI: 10.1016/j.psyneuen.2015.05.006
• Languages: English
• ISSNs: 0306-4530

Abstract

Highlights: Remitted recurrent MDD-patients show alterations in DHEAS and cortisol/DHEAS-ratio. These alterations do not change during a recurrent depressive episode. Morning cortisol/DHEAS ratio predicts recurrence over a 10-year follow-up. This suggests altered DHEAS is part of an endophenotypic vulnerability trait in MDD. This may be used to improve prevention of recurrence and cardiovascular comorbidity. Summary: Background: Major depressive disorder (MDD) has been associated with low dehydroepiandrosterone-sulphate (DHEAS), – particularly relative to high cortisol – although conflicting findings exist. Moreover, it is unclear whether low DHEAS is only present during the depressive state, or manifests as a trait that may reflect vulnerability for recurrence. Therefore, we longitudinally tested whether low DHEAS and high cortisol/DHEAS-ratio in recurrent MDD (I) reflects a trait, and/or (II) varies with depressive state. In addition, we tested associations with (III) previous MDD-episodes, (IV) prospective recurrence, and (V) effects of cognitive therapy. Methods: At study-entry, we cross-sectionally compared morning and evening salivary DHEAS and molar cortisol/DHEAS-ratio of 187 remitted recurrent MDD-patients with 72 matched controls. Subsequently, patients participated in an 8-week randomized controlled cognitive therapy trial. We repeated salivary measures after 3 months and 2 years. We measured clinical symptoms during a 10-year follow-up. Results: Remitted patients showed steeper diurnal DHEAS-decline ( p < .005) and a flatter diurnal profile of cortisol/DHEAS-ratio ( p < .001) than controls. We found no state-effect in DHEAS or cortisol/DHEAS-ratio throughout follow-up and no association with number of previous episodes. Higher morning cortisol/DHEAS-ratio predicted shorter time till recurrence over the 10-year follow-up in interaction with the effects of cognitive therapy ( p < .05). Finally, cognitive therapy did not influence DHEAS or cortisol/DHEAS-ratio. Conclusions: Diurnal profiles of DHEAS and cortisol/DHEAS-ratio remain equally altered in between depressive episodes, and may predict future recurrence. This suggests they represent an endophenotypic vulnerability trait rather than a state-effect, which provides a new road to understand recurrent depression and its prevention. Trial registration: www.isrctn.com/ISRCTN68246470 .